Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14003405 | 0.93 | CNR1 (0.53) | CNR1CYP2C9CYP2C19CYP3A4ADORA2A | |
| SCHEMBL4843834 | 0.89 | CNR1 (0.62) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL4838891 | 0.87 | CNR1 (0.59) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL4839993 | 0.86 | CNR1 (0.57) | CNR1CYP2C9CYP2C19CYP3A4ADORA2A | |
| SCHEMBL4836266 | 0.85 | CNR1 (0.57) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL4838798 | 0.85 | CNR1 (0.69) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL4835555 | 0.84 | CNR1 (0.55) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL4832161 | 0.84 | CNR1 (0.59) | CNR1CYP2C9CYP2C19CYP3A4ADORA2A | |
| SCHEMBL4839971 | 0.82 | CNR1 (0.62) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 | |
| SCHEMBL14003409 | 0.81 | CNR1 (0.52) | CNR1CYP2C9CYP2C19CYP3A4NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| WO-2006138734-A1 | TRIAZOLOPYRIMIDINE CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | CNR1, CNR2, GPR68 | CNR1 1/4885CYP2C9 487/4885CYP2C19 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.